Payment overview · 2025
General Payments
$1,597.31
87 reported records · 22 companies
Healthcare provider profile · identity verified
William Bailey, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CANTON, IL · NPI 1598020836
Verified facts
What the public records show
CMS Open Payments records show William Bailey, M.D. received $1,597.31 in general payments during 2025 across 87 reported records.
ABBVIE INC. accounted for 25.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $401.68 | 25.1% | 25 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $193.72 | 12.1% | 11 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $165.75 | 10.4% | 9 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $106.61 | 6.7% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $85.96 | 5.4% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $67.09 | 4.2% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $64.51 | 4.0% | 4 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $60.01 | 3.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $52.73 | 3.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $50.86 | 3.2% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $50.15 | 3.1% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $40.33 | 2.5% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $39.77 | 2.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.45 | 2.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.17 | 2.1% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $28.23 | 1.8% | 2 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $26.81 | 1.7% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $23.70 | 1.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.11 | 1.3% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $17.19 | 1.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.71 | 1.1% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $13.77 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,597.31 | 87 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $273.08 | 18 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $165.75 | 9 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $112.96 | 7 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $106.61 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $98.06 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $94.18 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $85.96 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $64.51 | 4 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $60.01 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $52.83 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $52.74 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $50.86 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $50.15 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $42.24 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $40.33 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $39.77 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.44 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $37.44 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $36.08 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $28.23 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $27.93 | 2 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $26.81 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.37 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $20.11 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.80 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.80 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $13.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 86 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 46 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 71 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
71 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
123 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 499 | 109 |
| Lisinopril | Lisinopril | 401 | 97 |
| Atorvastatin Calcium | Atorvastatin Calcium | 372 | 94 |
| Omeprazole | Omeprazole | 303 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 248 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 219 | 57 |
| Prednisone | Prednisone | 215 | 126 |
| Fluticasone Propionate | Fluticasone Propionate | 214 | 87 |
| Meloxicam | Meloxicam | 214 | 60 |
| Metformin Hcl | Metformin Hcl | 210 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 199 | 58 |
| Simvastatin | Simvastatin | 199 | 50 |
| Lorazepam | Lorazepam | 198 | 47 |
| Losartan Potassium | Losartan Potassium | 191 | 55 |
| Furosemide | Furosemide | 165 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 155 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 145 | 37 |
| Tramadol Hcl | Tramadol Hcl | 126 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 124 | 32 |
| Eliquis | Apixaban | 123 | 27 |
| Gabapentin | Gabapentin | 121 | 31 |
| Potassium Chloride | Potassium Chloride | 117 | 25 |
| Trazodone Hcl | Trazodone Hcl | 111 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 26 |
| Alprazolam | Alprazolam | 105 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 103 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 97 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 94 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 91 | 18 |
| Jardiance | Empagliflozin | 86 | 16 |
| Naproxen | Naproxen | 86 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 20 |
| Sertraline Hcl | Sertraline Hcl | 80 | 22 |
| Warfarin Sodium | Warfarin Sodium | 78 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 77 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 71 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 68 | 18 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 66 | 19 |
| Metformin Hcl Er | Metformin Hcl | 66 | 15 |
| Azithromycin | Azithromycin | 65 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 17 |
| Cephalexin | Cephalexin | 63 | 44 |
| Clonazepam | Clonazepam | 62 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 61 | 13 |
| Glipizide | Glipizide | 61 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 59 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 59 | 13 |
| Olanzapine | Olanzapine | 56 | 13 |
| Donepezil Hcl | Donepezil Hcl | 50 | 15 |
| Buspirone Hcl | Buspirone Hcl | 49 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 29 |
| Atenolol | Atenolol | 48 | 13 |
| Ibuprofen | Ibuprofen | 48 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 16 |
| Mounjaro | Tirzepatide | 46 | 13 |
| Xarelto | Rivaroxaban | 46 | suppressed |
| Carvedilol | Carvedilol | 44 | 12 |
| Bupropion Xl | Bupropion Hcl | 43 | 13 |
| Alendronate Sodium | Alendronate Sodium | 42 | 12 |
| Allopurinol | Allopurinol | 42 | 11 |
| Topiramate | Topiramate | 41 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 39 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 37 | 11 |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | 11 |
| Diazepam | Diazepam | 36 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 32 |
| Pregabalin | Pregabalin | 35 | suppressed |
| Levofloxacin | Levofloxacin | 34 | 24 |
| Mirtazapine | Mirtazapine | 34 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 13 |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Ozempic | Semaglutide | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Famotidine | Famotidine | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Nystatin | Nystatin | 25 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 17 |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 18 |
| Cilostazol | Cilostazol | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 13 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| V-Go 30 | Sub-Q Insulin Device, 30 Unit | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,597.31 · 87 records | ABBVIE INC. | AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, ENTRESTO, FARXIGA, FUROSCIX, JARDIANCE, JOURNAVX, Jornay PM, Kerendia, LEQVIO, MOUNJARO, NEXLETOL, NURTEC ODT, Ohtuvayre, Ozempic, QULIPTA, REXULTI, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, WAKIX, YUPELRI, ZAVZPRET, ZENPEP, ZEPBOUND, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error